Deira Trading Company
Eli Lilly’s fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.